Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110498 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Michelle Carnazza und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of R&D, General Nutraceutical Technology LLC, Briarcliff Manor, NY 10510, USA. Hauptthemen laut MEDLINE: Thyroid Cancer, Papillary, Thyroid Neoplasms, Signal Transduction, Biological Products. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Thyroid cancer (TC) represents the most prevalent endocrine malignancy, with papillary thyroid cancer (PTC) comprising approximately 80% of cases and accounting for the majority of annual incidence and mortality. PTC is generally confined to the thyroid gland and demonstrates an excellent prognosis after surgery, with a five-year survival rate exceeding 90%. Nevertheless, recurrence can occur, and the ten-year survival rate for the advanced PTC is below 50%. Even after effective successful surgical intervention, many still require ongoing surveillance, additional treatment, and lifelong thyroid hormone replacement, while facing the potential adverse effects such as hormone fluctuations, surgical complications, and sequelae of radioactive iodine exposure. Naturally occurring compounds have demonstrated anti-cancer properties and hence the potential to be used as therapeutic options, impacting the same drivers and pathways involved in the tumorigenesis of thyroid cancer. This narrative review focuses on the natural compounds’ convergence on molecular nodes of PI3K/Akt, MAPK, and JAK/STAT to overcome therapeutic resistance and restore apoptosis, highlighting their potential in advanced and recurrent PTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of R&D, General Nutraceutical Technology LLC, Briarcliff Manor, NY 10510, USA.
- Department of Pathology, Microbiology & Immunology, New York Medical College, Valhalla, NY 10595, USA.
- Department of Otolaryngology, New York Medical College, Valhalla, NY 10595, USA.
- Department of Dermatology, New York Medical College, Valhalla, NY 10595, USA.
ORCID-Profile: Jan Geliebter
Zitieren
APA
Carnazza, M., Yang, N., Tiwari, R. K., Geliebter, J., & Li, X. M. (2025). Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110498
Vancouver
Carnazza M, Yang N, Tiwari RK, Geliebter J, Li XM. Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110498
BibTeX
@article{Carnazza2025,
author = {Carnazza, Michelle and Yang, Nan and Tiwari, Raj K and Geliebter, Jan and Li, Xiu-Min},
title = {Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110498}
}
EUVIMED